Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 75%
filed 2026-07-14
Item 1.01
Jaguar Health's subsidiary Napo entered into a new three-year manufacturing and supply agreement with Alivus on July 9, 2026, to continue supplying crofelemer for Mytesi®, the company's FDA-approved prescription drug product. This is a material definitive agreement that secures the supply chain for the company's primary commercial product and includes minimum purchase commitments with potential financial obligations. While this is a renewal rather than a new relationship, the binding three-year commitment with specified minimum quantities and financial penalties for shortfalls constitutes a material agreement affecting the company's operational and financial obligations.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-14
Item 2.02
The Board declared a cash distribution of $0.09 per share to stockholders. This routine dividend distribution is material to investors as it affects shareholder returns and capital allocation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01
Trinity Capital announced on July 14, 2026, its intention to voluntarily transfer the listings of its common stock and senior notes from Nasdaq to the New York Stock Exchange and NYSE Texas, with trading expected to commence on or about July 27, 2026. This strategic relisting involves changes to ticker symbols and trading venues for both securities.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 2.01
Apollo-managed funds completed the acquisition of Emerald Holding, Inc. on July 14, 2026, for $5.03 per share in cash, resulting in a change of control and the cessation of Emerald's NYSE trading. The transaction also included the acquisition of Questex, LLC, creating a combined B2B experiential events and media platform, with Emerald becoming a wholly-owned subsidiary and its board members ceasing service.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-14
Item 5.07
This is a classic Item 5.07 disclosure reporting the final certified voting results from Gloo Holdings' 2026 annual meeting of stockholders held on July 13, 2026. The filing presents tabulated results for two proposals: election of three directors (Bishop Claude Alexander, Jr., John Furst, and Derek Green) and ratification of Crowe LLP as independent auditor. The disclosure includes vote counts (For, Against/Withheld, Abstentions, and Broker Non-Votes) certified by the inspector of elections, which is the standard format for shareholder vote results under Item 5.07.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 2.01
Ares Real Estate funds completed an all-cash acquisition of Whitestone REIT for $19.00 per share, valued at approximately $1.7 billion, resulting in a change of control and the company's delisting from NYSE. The transaction included the merger of Whitestone with Merger Sub and the merger of Whitestone's operating partnership with Merger OP, with Whitestone ceasing to exist as a publicly traded entity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01
Whitestone REIT notified NYSE on July 14, 2026 of the completion of its acquisition by Ares Real Estate funds and requested cessation of trading and delisting via Form 25. Trading was suspended on July 14, 2026, and the company intends to file Form 15 to deregister under Section 12(g).
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-07-14
Item 5.02
Six board members and officers departed from Whitestone REIT effective as of the Company Merger Effective Time, as a direct consequence of the completion of Ares' acquisition of the company.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 1.01
Strategic Storage Trust VI, Inc. entered into a definitive Agreement and Plan of Merger on July 14, 2026, to acquire Strategic Storage Growth Trust III, Inc. in an all-stock transaction. The merger combines two SmartStop-sponsored REITs and includes acquisition of 12 wholly-owned self-storage facilities, 50% equity interests in three unconsolidated real estate ventures, and beneficial interests in three DST-sponsored programs, with a combined company expected to have a total asset value of approximately $1.2 billion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-14
Item 1.01
Research Alliance Corp IV entered into multiple material definitive agreements in connection with its initial public offering, including an Underwriting Agreement, Investment Management Trust Agreement, Registration and Shareholder Rights Agreement, and Private Placement Shares Purchase Agreement. These agreements establish the company's capitalization and governance framework for pursuing a business combination.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-14
Item 3.02
Research Alliance Corp IV completed an unregistered private placement of 275,000 Class A ordinary shares to the Sponsor at $10.00 per share, generating $2.75 million in proceeds pursuant to Section 4(a)(2) of the Securities Act, simultaneously with the IPO closing.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-14
Item 5.02
Alan Musso and John Maslowski were appointed to the Board of Directors effective July 10, 2026, in connection with the Company's IPO, with concurrent appointments to the Audit, Nominating, and Compensation committees.
View raw filing on EDGAR →
8-K
Financial Other
confidence 65%
filed 2026-07-14
Item 8.01
Research Alliance Corp IV announced the pricing and closing of a $75 million initial public offering, establishing the company's public capitalization and status as a special purpose acquisition company (SPAC).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-14
Item 8.01
Erasca entered into an underwriting agreement on July 13, 2026 to issue and sell 31,428,572 shares of common stock at $17.50 per share, with expected net proceeds of approximately $516.0 million (or $593.5 million if the underwriters' 30-day option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders. The filing explicitly references the shelf registration statement on Form S-3 and prospectus supplement, confirming this is a registered offering rather than an unregistered private placement, but it remains a material dilutive equity issuance that would significantly affect investor assessment of ownership and capital structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-14
Item 8.01
The disclosure announces FDA clearance of an IND application for ATR 1072, enabling the company to initiate its Corventis™ Phase 1/2 clinical trial for PRKAG2 syndrome. This is a material regulatory milestone for a biopharmaceutical company's lead precision cardiology program, representing significant progress in clinical development. While not a specific named event type, this is clearly an operational/strategic milestone—the advancement of a key product candidate into human clinical trials—that would affect a reasonable investor's assessment of the company's pipeline and near-term prospects.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-14
Item 1.01
Banzai International completed a registered public offering of 327,273 shares of Class A common stock at $2.75 per share on July 14, 2026, generating approximately $0.9 million in gross proceeds, with an additional 45-day overallotment option for 36,364 shares. This registered equity issuance under an effective Form S-3 shelf registration statement dilutes existing shareholders and represents a material capital-raising event.
View raw filing on EDGAR →
8-K
Terminal Other
confidence 95%
filed 2026-07-14
Item 8.01
Churchill Capital Corp IX's board determined on July 14, 2026, that the company is unable to consummate a business combination by the August 6, 2026 deadline and has decided to cease operations, redeem all outstanding public shares at approximately $10.89 per share, liquidate, and delist from Nasdaq. This represents a terminal event materially threatening the registrant's continued existence—the company is winding up and dissolving entirely due to failure to complete its SPAC business combination objective.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 97%
filed 2026-07-14
Item 1.01
Sunbelt Rentals completed the issuance and sale of $1.2 billion in Senior Notes, consisting of $450 million in 4.950% notes due 2030 and $750 million in 5.650% notes due 2036, pursuant to an indenture dated July 14, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-14
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Shareholders held on July 11, 2026. The filing reports the outcomes of three proposals: election of directors (James W. Bernau and Sean M. Cary both elected with >91% support), ratification of Baker Tilly US, LLP as independent auditors (97.78% approval), and advisory approval of executive compensation (82.34% approval). This is a quintessential Item 5.07 disclosure of shareholder voting results at an annual meeting.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-14
Item 5.02
The Board appointed two new directors, Christopher Riccardi and Greg Voorhies, effective July 11, 2026, with terms expiring at the 2028 annual meeting. This is a clear director appointment disclosure under Item 5.02, and director appointments are material events affecting the composition and governance of the company's board.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-14
EX-99.1
The press release announces that Jinxin Technology has regained compliance with Nasdaq's Minimum Bid Price Requirement (Listing Rule 5550(a)(2)) after receiving a deficiency notice on January 29, 2026. The company evidenced a closing bid price at or above US$1.00 for 10 consecutive business days from June 26 to July 10, 2026, thereby curing the deficiency and closing the matter. This disclosure directly addresses a delisting risk — the company was previously non-compliant with a continued listing standard and faced potential delisting within a 180-day cure period, but has now remedied that condition.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 7.01
ADI Global Distribution is disclosing an investor day event held on July 14, 2026, in connection with its pending spin-off from Resideo Technologies. The filing includes a press release and investor presentation outlining ADI's standalone strategy, financial framework, and medium-term financial targets (4-6% revenue CAGR, >10% Adjusted EBITDA CAGR by 2030, $80M+ in run-rate operating savings). While the spin-off itself is a material M&A activity, this Item 7.01 disclosure focuses on the strategic and operational positioning of ADI as an independent company rather than the separation transaction mechanics, making it primarily an operational/strategic disclosure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
The press release announces the Australian Patent Office's allowance of Patent Application No. 2021290439 for "Treatment of Advanced Metastatic Cancer," which strengthens Can-Fite's intellectual property portfolio for Namodenoson in hepatocellular carcinoma and pancreatic cancer. This is a material operational/strategic milestone that extends patent protection in a major international market and supports the company's most advanced oncology programs, but it does not fit the specific event categories of earnings release, M&A activity, executive changes, or other defined types. The patent allowance is a significant development for a clinical-stage biotech company's pipeline protection and market exclusivity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
This press release announces Steakholder Foods' U.S. market entry with its Perfecta™ Premium Plant-Based Meat product line, including the arrival of the first shipment and planned distribution through KeHE Distributors across dozens of retail outlets in the Northeastern USA. This is a material operational and strategic milestone—the company's entry into a major new market with a branded consumer product—but does not fit the specific event categories (M&A, earnings, executive changes, debt, etc.). It represents a significant business development and product commercialization event that would affect a reasonable investor's assessment of the company's growth prospects and market execution.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
This press release announces a framework collaboration agreement with a leading global defense system integrator to supply radar systems for three projects, with initial orders already placed and additional orders anticipated in 2026-2027. The disclosure represents a material operational and commercial milestone—entry into a new high-value vertical (defense/homeland security) beyond automotive, with exclusive radar provider status and demonstrated customer commitment through initial deliveries. While not a discrete M&A transaction, it is a significant strategic partnership and customer win that would affect a reasonable investor's assessment of the company's growth prospects and market expansion.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-14
EX-99.3
This is a formal earnings release dated July 14, 2026, announcing Globavend's unaudited financial results for the six months ended March 31, 2026 (first half fiscal 2026). The document discloses revenue of US$14.8 million (8.0% increase), operating loss of US$369,978, net loss of US$30,887, and key operational metrics including 44% increase in average daily shipments. The release is material as it provides investors with periodic financial performance and operational updates essential to assessing the registrant's financial condition and business trajectory.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-14
Item 5.02
The filing discloses the appointment of Sarah M. Romano as Chief Financial Officer, effective August 3, 2026. While the disclosure also includes compensatory arrangements (base salary of $440,000, annual bonus eligibility, and stock option grant of 750,000 shares), the principal action is the appointment of a named executive officer to a C-suite position. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance structure.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 75%
filed 2026-07-14
Item 8.01
The disclosure describes a €20 million EIB loan that became due June 1, 2026, with the EIB reserving all rights and threatening enforcement action while negotiations continue. This represents a triggering event—a debt obligation in default or at imminent risk of default—that could accelerate financial obligations and materially affect the company's liquidity and financial position. While styled as "ongoing discussions," the EIB's reservation of rights and warning that enforcement is not contemplated only "while discussions remained ongoing" signals a covenant breach or technical default scenario typical of Item 2.04 disclosures.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
EX-99.1
The press release announces termination of a letter of intent for the acquisition of AI Financial Corporation's subsidiary Alt5 Sigma Canada, Inc. This is a material M&A event — the termination of a proposed transaction. The statement from Chief Strategy Officer Matthew Nicoletti explicitly states "Perpetuals has decided not to further pursue the acquisition" and "the earlier letter of intent has been terminated," which constitutes a material change in the status of a contemplated acquisition that would affect investor assessment of the company's strategic direction and capital allocation.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-07-14
EX-99.1
This is a press release announcing preliminary unaudited H1 2026 financial highlights, including revenue of approximately $11.4 million (up 115% versus H1 2025), cash position of $495 million, and reaffirmed FY 2026 guidance of 50%–100% revenue growth. The document explicitly states "Preliminary H1 2026 Financial Highlights (Unaudited)" and notes that "WISeKey expects to publish its full H1 2026 consolidated financial results in September 2026." This is a discrete earnings announcement for an interim period, not the periodic financial report itself.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-14
The Company received notification from Nasdaq on July 13, 2026, granting an extension of 180 calendar days (until January 4, 2027) to regain compliance with the Minimum Bid Price Rule. The disclosure explicitly states that failure to regain compliance by that date will result in written notification of delisting. This is a material delisting-risk disclosure under Item 3.01 equivalent, as it directly threatens the Company's continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-14
PVH Corp. announced the appointment of Alexis Rollier as Chief Financial Officer, effective early September 2026, replacing interim CFO Melissa Stone. The filing discloses a detailed employment agreement with compensation terms including $850,000 base salary, bonus opportunities up to 200% of base, and equity awards totaling approximately $2.825 million in PSUs, RSUs, and sign-on awards. This is a material executive appointment to a principal officer position.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-14
Item 5.02
Jeanne Nguyen, the Company's Chief Accounting Officer, departed effective July 8, 2026. This is a clear executive departure of a named officer responsible for accounting functions, which is material to investors' assessment of the registrant's financial reporting controls and governance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-14
Item 8.01
Churchill Capital Corp XI and Agility Robotics announced the confidential submission of a draft Form S-4 registration statement on July 13, 2026, in connection with their previously disclosed Merger Agreement. The filing discloses a material acquisition/business combination transaction expected to close in 2026, with approximately $620 million in gross proceeds, creating a publicly listed pure-play humanoid robotics company. This is a clear entry into a material merger and change of control transaction requiring shareholder approval.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-14
Item 5.02
The filing discloses the appointment of Paul Lapping as a director of Churchill Capital Corp XII effective July 13, 2026, along with his appointment to the compensation and audit committees and as audit committee chairperson. While the section also mentions director compensation agreements, the principal disclosed action is the appointment of a new director to the board and committee positions, making exec_appointment the most salient event type.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-14
Item 5.07
Oak Woods Acquisition Corp held an Extraordinary General Meeting on July 8, 2026, where shareholders voted to approve a Charter Amendment extending the business combination deadline from March 28, 2026 to March 28, 2027, with 2,398,953 votes in favor and 208,150 against, meeting the required two-thirds supermajority. The vote also approved an Adjournment Proposal, and 1,269,163 ordinary shares were tendered for redemption, resulting in a post-vote outstanding share count material to the company's equity base.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-14
Item 5.02
The disclosure centers on a revised letter agreement with CEO Stephen Willard that amends his compensatory arrangements, including removal of base salary deferral, establishment of an annual cash bonus program (45% target), modification of severance and change-of-control benefits, and acceleration of equity vesting from four years to three years. This is a material modification of executive compensation terms, not a departure or appointment.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-07-14
Item 8.01
This disclosure describes the consummation of Bleichroeder Acquisition Corp. III's initial public offering on July 8, 2026, involving the sale of 34.5 million units at $10.00 per unit (generating $345 million in gross proceeds) and concurrent private placement of 8.5 million warrants ($8.5 million). While IPOs are material capital-raising events, this is a blank-check/SPAC formation rather than a traditional operating company IPO or earnings release. The event does not fit neatly into the standard taxonomy categories (not earnings_release, not ma_activity, not debt_issuance in the traditional sense). The financial materiality is clear—$345 million raised—but the event type is ambiguous: it could be classified as a dilutive_issuance (equity capital raise), a financial_other (capital formation), or operational_other (strategic business event). Given the domain is financial but the specific type is unclear, other_material is most appropriate.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-14
Item 2.02
This is a clear earnings release disclosing Rocky Mountain Chocolate Factory's quarterly financial results for the three months ended May 31, 2026. The press release reports total revenue of $6.1 million, a net loss of $1.2 million ($(0.12) per share), and negative EBITDA of $(0.6) million, with detailed consolidated statements of operations and balance sheets attached as Exhibit 99.1. The deterioration in results compared to the prior year quarter (net loss increased from $(0.3) million to $(1.2) million) is material to investors' assessment of the company's financial condition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-14
The filing discloses the exercise of an underwriter option to purchase an additional 1,500,000 Class A ordinary shares, generating $30.0 million in gross proceeds. This is a dilutive equity issuance that increases share count and raises capital, fitting the definition of a dilutive_issuance. The materiality is clear given the substantial capital raised and shareholder dilution involved.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
This news release announces the peer-reviewed publication of Phase II clinical trial data for CardiolRx™ in the Journal of the American Heart Association, with the pivotal Phase III MAVERIC trial nearing completion. The publication of positive Phase II results in a peer-reviewed journal is a material operational/clinical milestone for a late-stage biopharmaceutical company, as it strengthens the scientific foundation for the ongoing Phase III pivotal trial and demonstrates clinical efficacy and safety. This is a discrete clinical/operational event distinct from periodic financial reporting.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-14
Item 5.02
Domino's appointed Michael C. Creedon, Jr. (former CEO of Dollar Tree) and Anneliese Olson (former President of HP's Imaging, Printing and Solutions division) to the Board of Directors effective July 15, 2026, increasing the Board size from eight to ten directors.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-14
Item 8.01
Corie S. Barry was appointed as Lead Independent Director of Domino's Board on July 14, 2026, replacing Richard L. Federico in that governance leadership role.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-14
Vale's Board of Directors elected Mr. Wilfred Theodoor Bruijn, an independent board member, to serve as Chairman of the Board of Directors, filling a vacancy that arose on July 6, 2026. The appointment of a Chairman is a material governance event affecting the registrant's leadership structure and would influence a reasonable investor's assessment of the company's governance and direction.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-14
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of San Francisco. Schedule A details three specific debt issuances with trade dates in July 2026, including a $15 million fixed-rate bond, a $1 billion variable-rate floater, and a $565 million variable-rate floater, totaling approximately $1.58 billion in new debt obligations. This is a classic Item 2.03 debt issuance disclosure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-14
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Des Moines. Schedule A lists multiple debt securities with trade dates of 7/8/2026 through 7/10/2026, including fixed-rate bonds and variable-rate floaters with principal amounts ranging from $10 million to $1.5 billion. The Bank explicitly states that "consolidated obligations issuance is material to the Bank," and Item 2.03 is the standard disclosure vehicle for debt issuance under 8-K rules.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-14
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Topeka. Schedule A details multiple debt securities issued on trade dates in July 2026, including fixed-rate bonds (ranging from 4.3% to 5.1% coupons) and variable-rate floaters totaling approximately $3.3 billion in principal. This is a classic debt issuance disclosure under Item 2.03, and the registrant explicitly acknowledges that "consolidated obligations issuance is material to the FHLBank."
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-14
Item 2.03
The filing discloses the creation of multiple direct financial obligations through the issuance of Consolidated Bonds by the Federal Home Loan Bank of Cincinnati. Schedule A lists 14 separate bond issuances with trade dates in July 2026, ranging from $1 million to $50 million in principal amount, with maturities from 2027 to 2046 and coupon rates from 4.125% to 5.890%. The filing explicitly states that "Consolidated Obligations issuance is material to the FHLB," and Item 2.03 is the standard disclosure vehicle for debt issuances. This represents a material creation of direct financial obligations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-14
Item 2.03
The filing discloses the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Chicago, with Schedule A detailing multiple debt securities issued on trade dates of 7/8/2026, 7/9/2026, and 7/10/2026, totaling approximately $115 million in principal across multiple tranches with varying maturity dates and coupon rates. The Bank explicitly states that "consolidated obligations issuance is material to the Bank," and Item 2.03 is the standard disclosure vehicle for creation of direct financial obligations.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-14
Item 5.02
Frank Nitkiewicz, the Executive Vice President, Chief Operating Officer and Chief Financial Officer, notified the Bank on July 8, 2026 of his intent to retire by March 31, 2027. The disclosure centers on the departure of a senior executive holding critical financial and operational roles (principal financial officer and principal operating officer). While the filing notes the Bank's intention to search for a successor, the principal disclosed action is Nitkiewicz's retirement, making this an exec_departure event.
View raw filing on EDGAR →